Thrombotic risk in COVID-19: a case series and case-control study

Stoneham, Simon M, Milne, Kate M, Nuttal, Elisabeth, Frew, Georgina H, Sturrock, Beattie R, Sivaloganathan, Helena, Ladikou, Eleni E, Drage, Stephen, Phillips, Barbara, Chevassut, Timothy J T and Eziefula, Alice C (2020) Thrombotic risk in COVID-19: a case series and case-control study. Clinical Medicine. pp. 1-6. ISSN 1470-2118

[img] PDF (Thrombotic Risk in COVID-19) - Accepted Version
Download (261kB)


Background: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) is extremely limited.

Methods: We describe 3 cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE.

Results: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1vs 1.2 µg/mL P <0.001).

Conclusion: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Brighton and Sussex Medical School > Global Health and Infection
Subjects: R Medicine
R Medicine > RB Pathology > RB127 Manifestations of disease
R Medicine > RM Therapeutics. Pharmacology
Depositing User: Timothy Chevassut
Date Deposited: 10 Jul 2020 10:00
Last Modified: 23 Feb 2022 09:44

View download statistics for this item

📧 Request an update